To clarify and strengthen findings regarding weight change trends after discontinuation of anti-obesity medications in response to reader feedback.
Key Findings:
A general trend of weight regain following drug discontinuation is confirmed, highlighting the need for ongoing management strategies.
No significant difference in weight regain between placebo-controlled and active-controlled trials.
Clarified the inclusion of 11 unique studies with 15 time-point data points, emphasizing the robustness of the analysis.
Interpretation:
The findings reinforce the understanding that discontinuation of anti-obesity medications typically leads to weight regain, regardless of the type of control in trials, underscoring the importance of continued support for patients.
Limitations:
Exclusion of older studies may limit the applicability of findings to current populations, particularly in understanding long-term effects.
Potential biases in the included studies may still affect results, necessitating cautious interpretation.
Conclusion:
The core conclusion regarding weight regain remains robust despite methodological clarifications and additional analyses, indicating a critical area for future research and clinical focus.
Researchers found that patients with higher waist circumference and lower grip strength had the greatest risk for developing type 2 diabetes during long-term follow-up.
